Amar U Kishan1, Nicholas G Nickols2, Daniel E Spratt3. 1. Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu. 2. Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. 3. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Abstract
Radiotherapy has curative potential for patients with newly diagnosed localized prostate cancer and biochemical recurrence after radical prostatectomy, and can offer durable treatment responses for patients with oligometastatic disease. The success of radiotherapy in these settings relies on an accurate understanding of the extent of disease that is present and the precise anatomic localization of sites of disease. In this mini review, we provide an overview of recent data evaluating the role of positron emission tomography for assessing prostate-specific membrane antigen distribution in guiding radiotherapy in these settings. PATIENT SUMMARY: This mini review examines current evidence for the use of prostate-specific membrane antigen positron emission tomography/computed tomography to guide radiotherapy for patients with newly diagnosed localized prostate cancer, those with recurrences after radical prostatectomy, and those with oligometastatic disease.
Radiotherapy has curative potential for patients with newly diagnosed localized prostate cancer and biochemical recurrence after radical prostatectomy, and can offer durable treatment responses for patients with oligometastatic disease. The success of radiotherapy in these settings relies on an accurate understanding of the extent of disease that is present and the precise anatomic localization of sites of disease. In this mini review, we provide an overview of recent data evaluating the role of positron emission tomography for assessing prostate-specific membrane antigen distribution in guiding radiotherapy in these settings. PATIENT SUMMARY: This mini review examines current evidence for the use of prostate-specific membrane antigen positron emission tomography/computed tomography to guide radiotherapy for patients with newly diagnosed localized prostate cancer, those with recurrences after radical prostatectomy, and those with oligometastatic disease.
Authors: Matthew Alberto; Arthur Yim; Nathan Papa; Shankar Siva; Joseph Ischia; Karim Touijer; James A Eastham; Damien Bolton; Marlon Perera Journal: Front Oncol Date: 2022-08-18 Impact factor: 5.738